We therefore conducted a retrospective, real-world analysis of efficacy, tolerability, and molecular responses to Ropeg-IFNa in JAK2 V617F-mutant MPNs including PV, ET, pre-PMF, and MPN-U treated at our tertiary center. Here, JAK2 is linked to essential thrombocythemia.